Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Operating Expenses (2023 - 2025)

Historic Other Operating Expenses for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $1.4 million.

  • Tonix Pharmaceuticals Holding's Other Operating Expenses fell 1209.0% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 8165.97%. This contributed to the annual value of $66.7 million for FY2024, which is 15564.57% up from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Other Operating Expenses is $1.4 million, which was down 1209.0% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Other Operating Expenses ranged from a high of $62.3 million in Q2 2024 and a low of -$29.7 million during Q2 2023
  • Moreover, its 3-year median value for Other Operating Expenses was $1.3 million (2024), whereas its average is -$1.3 million.
  • As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Other Operating Expenses skyrocketed by 30963.34% in 2024, and later tumbled by 9475.0% in 2025.
  • Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's Other Operating Expenses stood at -$28.7 million in 2023, then surged by 104.13% to $1.2 million in 2024, then grew by 15.55% to $1.4 million in 2025.
  • Its Other Operating Expenses was $1.4 million in Q3 2025, compared to $3.3 million in Q2 2025 and $943000.0 in Q1 2025.